Skip to main content
Top
Published in: Acta Diabetologica 2/2011

01-06-2011 | Original Article

Metabolic consequences of incorrect insulin administration techniques in aging subjects with diabetes

Authors: Sandro Gentile, Mariano Agrusta, Giuseppina Guarino, Lucia Carbone, Vincenzo Cavallaro, Iarba Carucci, Felice Strollo

Published in: Acta Diabetologica | Issue 2/2011

Login to get access

Abstract

Only few insulin-treated (IT) people with diabetes mellitus (DM) reach the target due to poor compliance and/or to sedentary lifestyle and/or to inadequate treatment regimen. The latter may be also brought about by often overlooked factors including insulin injection into altered skin areas, often brought about by incorrect habits, namely needle reutilization or poor compliance to the suggestion to continuously rotate skin injection areas. The aim of our study was to evaluate the rate of skin lesions within the sites commonly used for insulin injection in our IT DM patients and to verify whether a short-acting insulin analogue yielded different metabolic effects when injected in altered vs. normal skin areas. One hundred and eighty well-trained IT people with type 1 and type 2 DM (64 ± 15 years of age) consecutively referring to our unit underwent a standard clinical examination involving an accurate skin inspection protocol meant at looking for any alterations eventually affecting all possible injection sites, including bruising, multiple needle pricks and lipodystrophic nodules (LN). They were also tested for HPLC HbA1c determination and asked to fill in a standard questionnaire on injection habits. Furthermore, seven male, T1DM glulisine–glargine basal-bolus-treated patients in this group were randomly injected 10 IU glulisine into either normal skin (NS) or an LN by a nurse before a standard, 405 kcal breakfast, for blood glucose and free insulin determination at 0, 30, 45, 60, 75, 90, 120 and 150 min. More lesions were found in people over sixty (P < 0.01) and in women (P < 0.05). A higher prevalence of HbA1c >7.5% was found in patients with lesions (with an O.R. of 3.74) and further confirmed by data obtained from head-to-head comparison of insulin injection into an LN and NS. In fact, injection into an LN proved to impair and slow down insulin absorption, resulting in a higher absolute value and a larger variability of blood glucose levels than those observed by utilizing NS. This suggests us to pay more attention to all aspects of patient–team relationship to try and obtain good metabolic control in all people with diabetes and even more in the elderly.
Literature
1.
go back to reference Nicolucci A, Ciccarone E, Consoli A et al (2000) Relationship between patient practice-oriented knowledge and metabolic control in intensively treated type 1 diabetic patients: results of the validation of the knowledge and practices diabetes questionnaire. Diabetes Nutr Metab 13:276–283PubMed Nicolucci A, Ciccarone E, Consoli A et al (2000) Relationship between patient practice-oriented knowledge and metabolic control in intensively treated type 1 diabetic patients: results of the validation of the knowledge and practices diabetes questionnaire. Diabetes Nutr Metab 13:276–283PubMed
2.
go back to reference Gin H, Hanaire-Broutin H (2005) Reproducibility and variability in the action of injected insulin. Diabetes Metab 31:7–13PubMedCrossRef Gin H, Hanaire-Broutin H (2005) Reproducibility and variability in the action of injected insulin. Diabetes Metab 31:7–13PubMedCrossRef
3.
go back to reference Guerci B, Suavenet JP (2005) Subcutaneous insulin: pharmacokinetic variability and glycemic variability. Diabetes Metab 31:454–457 Guerci B, Suavenet JP (2005) Subcutaneous insulin: pharmacokinetic variability and glycemic variability. Diabetes Metab 31:454–457
4.
go back to reference Young RJ, Steel MJ, Frier BM, Duncan LJ (1981) Insulin injection sites in diabetes: a neglected area? BMJ 283:349PubMedCrossRef Young RJ, Steel MJ, Frier BM, Duncan LJ (1981) Insulin injection sites in diabetes: a neglected area? BMJ 283:349PubMedCrossRef
5.
go back to reference Hambridge K (2007) The management of lipodystrophy in diabetes care. Br J Nurs 16:520–524PubMed Hambridge K (2007) The management of lipodystrophy in diabetes care. Br J Nurs 16:520–524PubMed
6.
go back to reference Richardson T, Kerr D (2003) Skin-related complications of insulin therapy: epidemiology and emerging management strategies. Am J Clin Dermatol 4:661–667PubMedCrossRef Richardson T, Kerr D (2003) Skin-related complications of insulin therapy: epidemiology and emerging management strategies. Am J Clin Dermatol 4:661–667PubMedCrossRef
7.
go back to reference Schiazza L, Ocella C, Bleidi D, Rampini E (1990) Insulin lipohypertrophy. J Am Acad Dermatol 104:145–149 Schiazza L, Ocella C, Bleidi D, Rampini E (1990) Insulin lipohypertrophy. J Am Acad Dermatol 104:145–149
8.
go back to reference Fujikura J (2005) Insulin-induced lipohypertrophy: report of a case with histopathology. Endocrine J 51:623–628CrossRef Fujikura J (2005) Insulin-induced lipohypertrophy: report of a case with histopathology. Endocrine J 51:623–628CrossRef
9.
go back to reference Wallymahmed ME, Littler P, Clegg C et al (2004) Nodules of fibrocollagenous scar tissue induced by subcutaneous insulin injections: a cause of poor diabetic control. Postgrad Med J 80(950):732–733PubMedCrossRef Wallymahmed ME, Littler P, Clegg C et al (2004) Nodules of fibrocollagenous scar tissue induced by subcutaneous insulin injections: a cause of poor diabetic control. Postgrad Med J 80(950):732–733PubMedCrossRef
10.
go back to reference Lopez X, Castells M, Ricker A, Velazques EF et al (2008) Human insulin analog-induced lipoatrophy. Diabetes Care 31:442–444PubMedCrossRef Lopez X, Castells M, Ricker A, Velazques EF et al (2008) Human insulin analog-induced lipoatrophy. Diabetes Care 31:442–444PubMedCrossRef
11.
go back to reference Géloën A, Collet AJ, Guay G, Bukowiecki LJ (1989) Insulin stimulates in vivo cell proliferation in white adipose tissue. Am J Physiol 256:C190–C196PubMed Géloën A, Collet AJ, Guay G, Bukowiecki LJ (1989) Insulin stimulates in vivo cell proliferation in white adipose tissue. Am J Physiol 256:C190–C196PubMed
12.
go back to reference Johansson UB, Amsberg S, Hannerz L et al (2005) Impaired absorption of insulin aspart from lipoypertrophic injecton sites. Diabetes Care 28:2025–2027PubMedCrossRef Johansson UB, Amsberg S, Hannerz L et al (2005) Impaired absorption of insulin aspart from lipoypertrophic injecton sites. Diabetes Care 28:2025–2027PubMedCrossRef
13.
go back to reference Gin H, Hanaire-Brutin H (2005) Reproducibility and variability in the action of injected insulin. Diabetes Metab 31:7–13PubMedCrossRef Gin H, Hanaire-Brutin H (2005) Reproducibility and variability in the action of injected insulin. Diabetes Metab 31:7–13PubMedCrossRef
14.
go back to reference Gentile S, Carbone L, Guarino G, De Blasi V et al (2007) Alterazioni di cute e sottocute da somministrazione di insulina e compenso glico-metabolico nel diabetico tipo 2 insulino-trattato. In: Atti XVI congresso nazionale AMD. Pacini, Pisa, pp 246–250 Gentile S, Carbone L, Guarino G, De Blasi V et al (2007) Alterazioni di cute e sottocute da somministrazione di insulina e compenso glico-metabolico nel diabetico tipo 2 insulino-trattato. In: Atti XVI congresso nazionale AMD. Pacini, Pisa, pp 246–250
15.
go back to reference The Diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC) study research group (2005). Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353: 2643–2653 The Diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC) study research group (2005). Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353: 2643–2653
16.
go back to reference Stratton I, Adler AL, Neil HA et al (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 21:405–412CrossRef Stratton I, Adler AL, Neil HA et al (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 21:405–412CrossRef
17.
go back to reference Gaede P, Vedel P, Larsen N et al (2003) Multifactorial intervention and cardiovasculardisease in patients with type 2 diabetes. N Engl J Med 348:383–393PubMedCrossRef Gaede P, Vedel P, Larsen N et al (2003) Multifactorial intervention and cardiovasculardisease in patients with type 2 diabetes. N Engl J Med 348:383–393PubMedCrossRef
18.
go back to reference Rydén L, Standl E, Bartnik M, Van den Berghe G et al (2007) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The task force on diabetes and cardiovascular diseases of the European society of cardiology (ESC) and of the European association for the study of diabetes (EASD). Eur Heart J 28:88–136PubMedCrossRef Rydén L, Standl E, Bartnik M, Van den Berghe G et al (2007) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The task force on diabetes and cardiovascular diseases of the European society of cardiology (ESC) and of the European association for the study of diabetes (EASD). Eur Heart J 28:88–136PubMedCrossRef
19.
go back to reference Italian Standards for Diabetes Mellitus (2007) In: Bonomo M et al (eds) Infomedica, Turin, pp 43–45 Italian Standards for Diabetes Mellitus (2007) In: Bonomo M et al (eds) Infomedica, Turin, pp 43–45
Metadata
Title
Metabolic consequences of incorrect insulin administration techniques in aging subjects with diabetes
Authors
Sandro Gentile
Mariano Agrusta
Giuseppina Guarino
Lucia Carbone
Vincenzo Cavallaro
Iarba Carucci
Felice Strollo
Publication date
01-06-2011
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 2/2011
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-009-0172-x

Other articles of this Issue 2/2011

Acta Diabetologica 2/2011 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.